Quick Answer
TransMedics Group, Inc. reported Cash and Equivalents of $394.81 million for fiscal year 2023.
TransMedics Group, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $394.81M | +96.2% |
| 2022 | $201.18M | +686.5% |
| 2021 | $25.58M | +4.1% |
| 2020 | $24.58M | +22.3% |
| 2019 | $20.09M | -0.7% |
| 2018 | $20.24M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $330.09M | -22.7% | -9.0% |
| June 30, 2024 | $362.75M | -37.7% | +3.6% |
| March 31, 2024 | $350.22M | +79.3% | -18.0% |
| September 30, 2023 | $427.11M | +108.9% | -26.6% |
| June 30, 2023 | $582.21M | +1816.0% | +198.0% |
| March 31, 2023 | $195.38M | +991.7% | -4.4% |
| September 30, 2022 | $204.46M | +808.9% | +572.9% |
| June 30, 2022 | $30.39M | +20.0% | +69.8% |
- TransMedics Group, Inc. showed an increase of +96.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2023 period, TransMedics Group, Inc.’s cash and equivalents has grown by 1850.6% (from $20.24 million to $394.81 million).
- The most recent figure is from TransMedics Group, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on February 27, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: